Angiogenesis and peptide therapy: what new blood-vessel growth has to do with recovery

Angiogenesis is the small word for a load-bearing idea. New blood vessels growing in. It happens every time tissue has to be rebuilt — a torn tendon, a closing wound, a recovering muscle, a transplanted graft. The cells doing the repair work need a fresh blood supply to do it, and the body builds one specifically for them.

That same biology is the load-bearing claim under two peptides on the FDA’s July 23, 2026 review docket: BPC-157 and TB-500. Both get sold for injury recovery. Both rest their entire animal mechanism story on the proposition that injecting the peptide pushes new blood vessels into damaged tissue. Here is what that means, where the evidence sits, and the question the same biology raises that nobody in the marketing brings up.

What angiogenesis actually is

Every cell in the body is within a few cell-widths of a capillary. That isn’t ornamental. It’s the only way the cell gets oxygen, glucose, and the signalling molecules that tell it what to do. When tissue is damaged — a tear, a cut, an infarct — the local supply is broken, and the cells that need to repair the damage are starved and signal-deaf.

Angiogenesis is the body’s solution. Endothelial cells in nearby capillaries start dividing, sprouting outward toward the wound, building new tubes, and connecting them up to existing circulation. The new vessels carry inflammatory cells in to clear the debris, then carry the cells needed for rebuilding — fibroblasts, satellite cells, stem cells — back to the place where the work has to be done. Without angiogenesis, healing stalls.

It is also one of the body’s tightly controlled processes. Healthy adult tissue almost never grows new vessels — the system stays off except during the menstrual cycle, pregnancy, and wound repair. The off-state matters: angiogenesis turned on at the wrong time is one of the things tumours need to grow past a few millimetres. The same biology that drives healing is the biology cancer hijacks. That is the trade-off any angiogenic agent walks into.

The BPC-157 angiogenesis-and-NO story

BPC-157 is a fifteen-amino-acid peptide — a partial sequence of body protection compound, a gastric juice protein — and its proposed mechanism, developed across three decades of animal work by Predrag Sikirić’s group at the University of Zagreb, runs through angiogenesis and the nitric oxide (NO) pathway. In rats with damaged tendons, ligaments, intestines, eyes, and brain tissue, BPC-157 administration is reported to accelerate angiogenesis at the injury site, modulate NO signalling, and shorten the repair timeline.

The 2025 Pharmaceuticals literature and patent review by Józwiak and colleagues surveys the breadth of that animal evidence base and the multifunctional activities the BPC-157 literature now claims. The review raised the cancer-relevance question implicitly — anything that drives angiogenesis as a primary mechanism has to be evaluated for the possibility of promoting blood-vessel growth into early or occult tumours.

Sikirić and colleagues replied in the same journal — a published comment exchange titled BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide — arguing the mechanism is best understood as cytoprotection through controlled NO signalling rather than tumour-promoting angiogenesis, citing decades of animal work in which exogenous BPC-157 did not increase tumour incidence. The exchange is unresolved. Both sides rest on animal data. The human pharmacology that would settle the question has not been characterised.

The TB-500 actin and Ac-SDKP story

TB-500 in the grey market refers, inconsistently, to either synthetic full-length thymosin β4 (Tβ4, 43 amino acids) or to shorter truncations of it. The published animal-model evidence is almost entirely on full-length Tβ4 — the synthetic short-fragment products do not share the same evidence base.

The 2010 Philp and Kleinman review in the Annals of the New York Academy of Sciences is the canonical animal-mechanism summary. Tβ4 promotes cell migration, supports new blood-vessel growth, and reduces local inflammation in dermal, corneal, cardiac, and other wound-repair settings in animals. The peptide does that primarily by binding and regulating monomeric (G) actin inside cells, which in turn governs the polymerised actin cytoskeleton — the structure cells rebuild every time they move, divide, or extend a process toward a healing front.

There is also a metabolite story. Wang and colleagues (2022, Int J Mol Sci) characterised the Tβ4-POP-Ac-SDKP axis: prolyl oligopeptidase hydrolyses thymosin β4 to release Ac-SDKP, the N-terminal tetrapeptide, which is itself anti-fibrotic and pro-angiogenic across hepatic, renal, cardiac, and pulmonary tissue in animal fibrosis models. Some grey-market TB-500 products are essentially Ac-SDKP rather than full-length Tβ4 — the molecule is shorter, the evidence base sits in a different mechanism literature, and the two cannot be cited interchangeably.

The tendon-repair claim — the version of TB-500 marketing most readers have run into — is where the evidence base thins out. Wu and colleagues (2020, Mater Sci Eng C) loaded Tβ4 onto electrospun nanofiber scaffolds and showed improved migration, proliferation, and tenogenic differentiation in human stem cells. That work is strictly in vitro — cells in a dish, on a scaffold. No animal tendon injection. No human tendon injection. The paper is frequently miscited as evidence of tendon repair when it is a tissue-engineering paper, not an injection study.

What the human file does not contain

For both peptides, the human angiogenesis evidence is essentially nothing.

BPC-157 has one registered Phase 2 trial — NCT07437547, an RCT of BPC-157 for acute hamstring muscle strain repair, sponsor Hudson Biotech, first posted February 2026, status recruiting. No results. The trial is the first registered controlled human study of BPC-157 in an injury-recovery indication; that is itself a first. The mechanism it will read out on is clinical repair, not direct measurement of angiogenesis in human tissue. Even a clean positive result will leave the angiogenesis claim itself inferred rather than measured.

TB-500 has no registered controlled human trial for tendon, wound, or muscle indications. The synthetic full-length thymosin β4 explored in earlier clinical programs is a different research context from the grey-market product, and what gets sold as TB-500 does not consistently match the full-length molecule those programs studied.

The 2025 Vasireddi, Hahamyan and Salata systematic review in HSS Journal captures the position honestly for BPC-157: an emerging therapeutic with promising preclinical mechanism evidence and an evidence base anchored in animal models rather than registered human trials. The same framing applies to TB-500.

The question both peptides have to answer

If the proposed mechanism is angiogenesis, the question that mechanism always raises is whether exogenous dosing drives blood-vessel growth selectively into damaged tissue, or whether it also feeds vasculature into tissues that should not be growing new vessels — early or occult tumours being the worry that gets named in the cancer literature. The Sikirić-Józwiak exchange is exactly that question for BPC-157. The TB-500 / Tβ4 literature has the same question on its file even though it is less actively debated in print.

Neither peptide has been carried through the long-term human safety studies that would close that question. The animal record is, in fairness, large and largely reassuring on tumour incidence within the dosing windows tested. That is not the same as a human carcinogenicity dataset across years of exposure in the population currently buying these compounds.

The regulatory positioning

Both BPC-157 and TB-500 are on the July 23, 2026 FDA Pharmacy Compounding Advisory Committee docket per Federal Register notice 2026-07361. The reviewed indications are revealing. BPC-157 is being evaluated for ulcerative colitis — a mucosal-protection indication consistent with the gastric-juice biology the compound was isolated from. TB-500 (free base and acetate forms) is being evaluated for wound healing, which is the indication closest to the published Tβ4 animal-model evidence. Neither indication is tendon repair, which is what most of the off-label market is buying for.

That mismatch matters. A favourable PCAC vote on either compound would open the molecule up to be compounded by US-licensed pharmacies for the specific reviewed indication — UC for BPC-157, wound healing for TB-500 — not for the indications the off-label market is built around. We covered how PCAC reviews actually work in What is the PCAC.

The cancer-safety question is the unfinished file

Growing new blood vessels into adult tissue is one of those processes the body keeps almost entirely off except during repair and reproduction. Angiogenesis is what tumours need to scale; the same control system has to stay tight enough to keep stray growth from being fed.

Mimicking that biology with a peptide is mechanistically plausible. It is also, structurally, where a clean human safety dataset matters most — and where the published file for these two compounds is at its thinnest.

What would actually close the cancer-relevance question for either peptide?

A long-term human pharmacokinetic and carcinogenicity dataset, not a series of short-window animal experiments. Independent replication of the Sikirić group’s NO-and-cytoprotection mechanism work outside the originating lab. Tumour-incidence surveillance in the population currently dosing — the off-label injury-recovery cohort, multi-year, with active follow-up rather than passive case-report drift. And, for BPC-157, the hamstring trial currently recruiting reading out without raising adverse-event signals it wasn’t powered to detect.

None of those studies is scheduled. The Sikirić-Józwiak exchange is the closest thing in print to an attempt at the question, and it sits unresolved on animal data.

Wolverine Health is being built around the version of either prescription where the supervising physician has the trial readouts in front of them and the dispensing pharmacy is US-licensed against a reviewed indication. Join the waitlist for a note the day any of those files actually fills.